{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:50:44Z","timestamp":1789581044439,"version":"build-2803163510"},"reference-count":19,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Postgraduate Medicine"],"published-print":{"date-parts":[[2021,1,2]]},"DOI":"10.1080\/00325481.2020.1823724","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T18:38:24Z","timestamp":1603996704000},"page":"71-81","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":50,"title":["Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials"],"prefix":"10.1080","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0807-2167","authenticated-orcid":false,"given":"Margaret","family":"Moline","sequence":"first","affiliation":[{"name":"Neurobiology Business Group, Eisai Inc., Woodcliff Lake, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8332-6687","authenticated-orcid":false,"given":"Gary","family":"Zammit","sequence":"additional","affiliation":[{"name":"Clinilabs Drug Development Corporation, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8198-4328","authenticated-orcid":false,"given":"Jane","family":"Yardley","sequence":"additional","affiliation":[{"name":"Neurobiology Business Group, Eisai Ltd., Hatfield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3475-2708","authenticated-orcid":false,"given":"Kate","family":"Pinner","sequence":"additional","affiliation":[{"name":"Neurobiology Business Group, Eisai Ltd., Hatfield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-4237","authenticated-orcid":false,"given":"Dinesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Neurobiology Business Group, Eisai Inc., Woodcliff Lake, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9307-1833","authenticated-orcid":false,"given":"Carlos","family":"Perdomo","sequence":"additional","affiliation":[{"name":"Neurobiology Business Group, Eisai Inc., Woodcliff Lake, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-5668","authenticated-orcid":false,"given":"Jocelyn Y.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Neurobiology Business Group, Eisai Inc., Woodcliff Lake, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00021-6"},{"key":"e_1_3_5_3_1","unstructured":"US Food and Drug Administration. Evaluating drug effects on the ability to operate a motor vehicle: guidance for industry 2017. [cited 2019 Aug 9]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/evaluating-drug-effects-ability-operate-motor-vehicle"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsmc.2017.03.011"},{"key":"e_1_3_5_5_1","first-page":"2015607148","article-title":"Residual effects of sleep medications are commonly reported and associated with impaired patient-reported outcomes among insomnia patients in the United States","author":"Fitzgerald T","year":"2015","unstructured":"Fitzgerald T, Vietri J. Residual effects of sleep medications are commonly reported and associated with impaired patient-reported outcomes among insomnia patients in the United States. Sleep Disord. 2015; 2015607148.","journal-title":"Sleep Disord"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17010050"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/15389588.2013.830211"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-013-0294-y"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S73224"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.5168"},{"key":"e_1_3_5_11_1","unstructured":"Eisai Inc. DAYVIGO (lemborexant) [Prescribing Information]. 2019. Woodcliff Lake NJ: Eisai Inc."},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.241422"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.817"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18254"},{"key":"e_1_3_5_15_1","article-title":"Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2 [published online ahead of print, 2020 Jun 26]","author":"K\u00e4rpp\u00e4 M","unstructured":"K\u00e4rpp\u00e4 M, Yardley J, Pinner K, et al. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2 [published online ahead of print, 2020 Jun 26]. Sleep. 2020;43(9):zsaa123.","journal-title":"Sleep. 2020;43(9):zsaa123"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.6800"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsy260"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.8294"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.3482"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1417.002"}],"container-title":["Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/00325481.2020.1823724","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T13:48:59Z","timestamp":1696513739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/00325481.2020.1823724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,2]]}},"alternative-id":["10.1080\/00325481.2020.1823724"],"URL":"https:\/\/doi.org\/10.1080\/00325481.2020.1823724","relation":{},"ISSN":["0032-5481","1941-9260"],"issn-type":[{"value":"0032-5481","type":"print"},{"value":"1941-9260","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-07-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}